The present invention relates to crystalline acalabrutinib L-pyroglutamate and crystalline acalbrutinib L-malate and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms, preferably in a predetermined and/or effective amount and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers such as mantle cell lymphoma and/or chronic lymphocytic leukaemia.
